# US 2020/0399673 A1 · Assessing and treating functional gastrointestinal disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0399673 A1
- Document ID: US20200399673A1
- Status: Published application
- Kind: A1
- Application number: 16/857,965
- Filed: 2020-04-24
- Published: 2020-12-24
- Earliest claimed: 2019-04-30
- Assignees: Mayo Foundation for Medical Education and Research
- Applicants: Mayo Foundation for Medical Education and Research
- Inventors: Purna C. Kashyap
- Web page: https://patentgrep.com/patent/US20200399673A1

## CPC

- C08G 18/7664: {containing alkylene polyphenyl groups}
- C12Q 1/06: Quantitative determination
- C04B 26/16: Polyurethanes
- C04B 28/02: containing hydraulic cements other than calcium sulfates
- C08G 18/4288: {modified by higher fatty oils or their acids or by resin acids}
- C09D 175/06: from polyesters
- C09D 175/08: from polyethers
- C09J 175/06: from polyesters
- F16L 1/24: Floats; Weights
- C04B 2111/00706: {around pipelines or the like}
- C08G: MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C04B: LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE {(roofing granules E04D7/005)}; CERAMICS (devitrified glass-ceramics C03C10/00); REFRACTORIES; TREATMENT OF NATURAL STONE
- C09D: COATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR (cosmetics A61K; processes for applying liquids or other fluent materials to surfaces, in general, B05D; staining wood B27K5/02; glazes or vitreous enamels C03C; natural resins, French polish, drying-oils, driers, turpentine, per se, C09F; polishing compositions other than French polish, ski waxes C09G; adhesives or use of materials as adhesives C09J; materials for sealing or packing joints or covers C09K3/10; materials for stopping leaks C09K3/12; processes for the electrolytic or electrophoretic production of coatings C25D)
- C09J: ADHESIVES; NON-MECHANICAL ASPECTS OF ADHESIVE PROCESSES IN GENERAL; ADHESIVE PROCESSES NOT PROVIDED FOR ELSEWHERE; USE OF MATERIALS AS ADHESIVES (preparation of glue or gelatine C09H)
- F16L: PIPES; JOINTS OR FITTINGS FOR PIPES; SUPPORTS FOR PIPES, CABLES OR PROTECTIVE TUBING; MEANS FOR THERMAL INSULATION IN GENERAL

## Abstract

This document relates to methods and materials involved in assessing and/or treating a mammal having a functional gastrointestinal disorder (FGID) such as irritable bowel syndrome (IBS). For example, methods and materials provided herein can be used for determining if a mammal having a FGID is likely to respond to a particular FGID treatment. This document also provides methods and materials for treating a mammal having a FGID.

## Claims

### Claim 1

A method for treating a mammal having a functional gastrointestinal disorder (FGID), wherein said method comprises:
identifying said mammal as having a small intestinal microbiome comprising two or more microbes selected from the group consisting of Anaeroglobus species, Erwinia species, Escherichia species, Staphylococcus species, Scardovia species, Bifidobacterium species, Lactobacillus species, Olsenella species, Slackia species, and Shuttleworthia species; and
administering an antibiotic to said mammal.

### Claim 2 (depends on 1)

The method of claim 1, wherein said mammal is a human.

### Claim 3 (depends on 1)

The method of claim 1, wherein said FGID is irritable bowel syndrome (IBS).

### Claim 4 (depends on 1)

The method of claim 1, wherein said identifying step comprises obtaining a sample from the small intestine of said mammal and determining the small intestinal microbiome within said sample.

### Claim 5 (depends on 4)

The method of claim 4, wherein said sample is a fecal sample or a duodenal aspirate sample.

### Claim 6 (depends on 1)

The method of claim 1, wherein said antibiotic is a narrow-spectrum antibiotic.

### Claim 7 (depends on 6)

The method of claim 6, wherein said antibiotic is selected from the group consisting of tungsten, a phage therapy, Debio 1452, and a bacteriocin.

### Claim 8

A method for treating a FGID, wherein said method comprises administering an antibiotic to a mammal that has said FGID and that was identified as having a small intestinal microbiome comprising two or more microbes selected from the group consisting of Anaeroglobus species, Erwinia species, Escherichia species, Staphylococcus species, Scardovia species, Bifidobacterium species, Lactobacillus species, Olsenella species, Slackia species, and Shuttleworthia species.

### Claim 9 (depends on 8)

The method of claim 8, wherein said mammal is a human.

### Claim 10 (depends on 8)

The method of claim 8, wherein said FGID is IBS.

### Claim 11 (depends on 8)

The method of claim 8, wherein said antibiotic is a narrow-spectrum antibiotic.

### Claim 12 (depends on 11)

The method of claim 11, wherein said antibiotic is selected from the group consisting of tungsten, a phage therapy, Debio 1452, and a bacteriocin.

### Claim 13

A method for treating a mammal having a FGID, wherein said method comprises:
identifying said mammal as having a small intestinal microbiome comprising two or more microbes selected from the group consisting of Anaeroglobus species, Erwinia species, Escherichia species, Staphylococcus species, Scardovia species, Bifidobacterium species, Lactobacillus species, Olsenella species, Slackia species, and Shuttleworthia species; and comprising a reduced level of two or more microbes selected from the group consisting of Lachnoanaerobaculum species, Prevotella species, Leptotrichia species, Catonella species, Gemella species, Neisseria species, Haemophilus species, and Streptococcus species; and
administering a probiotic to said mammal.

### Claim 14 (depends on 13)

The method of claim 13, wherein said mammal is a human.

### Claim 15 (depends on 13)

The method of claim 13, wherein said FGID is IBS.

### Claim 16 (depends on 13)

The method of claim 13, wherein said identifying step comprises obtaining a sample from the small intestine of said mammal and determining the small intestinal microbiome within said sample.

### Claim 17 (depends on 16)

The method of claim 16, wherein said sample is a fecal sample or a duodenal aspirate sample.

### Claim 18 (depends on 13)

The method of claim 13, wherein said probiotic is selected from the group consisting of Lachnoanaerobaculum species, Megasphaera species, Leptotrichia species, Catonella species, Gemella species, Peptostreptococcus species, Prevotella species, Haemophilus species, Campylobacter species, Neisseria species, Streptococcus species, Rothia species, Actinomyces species, and Granulicatella species.

### Claim 19

A method for treating a FGID, wherein said method comprises administering an antibiotic to a mammal that has said FGID and that was identified as having a small intestinal microbiome comprising two or more microbes selected from the group consisting of Anaeroglobus species, Erwinia species, Escherichia species, Staphylococcus species, Scardovia species, Bifidobacterium species, Lactobacillus species, Olsenella species, Slackia species, and Shuttleworthia species; and comprising a reduced level of two or more microbes selected from the group consisting of Lachnoanaerobaculum species, Prevotella species, Leptotrichia species, Catonella species, Gemella species, Neisseria species, Haemophilus species, and Streptococcus species.

### Claim 20 (depends on 19)

The method of claim 19, wherein said mammal is a human.

### Claim 21 (depends on 19)

The method of claim 19, wherein said FGID is IBS.

### Claim 22 (depends on 19)

The method of claim 19, wherein said probiotic is selected from the group consisting of Lachnoanaerobaculum species, Megasphaera species, Leptotrichia species, Catonella species, Gemella species, Peptostreptococcus species, Prevotella species, Haemophilus species, Campylobacter species, Neisseria species, Streptococcus species, Rothia species, Actinomyces species, and Granulicatella species.